CRISPRs Revenue Jumps 1,000%, But Why the Stock Isnt Soaring

CRISPR Therapeutics(CRSP), ranking by market capitalization reported its fiscal 2026 Q2 earnings on Aug 03rd, 2026.

CRISPR Therapeutics reported a significant beat on both top and bottom lines for the second quarter of 2026. Revenue of $10.18 million surpassed analyst estimates of $7.43 million, while the GAAP EPS of -$0.94 beat the consensus estimate of -$1.20. Management provided optimistic forward guidance, highlighting clinical updates for key pipeline assets in the second half of 2026, reinforcing investor confidence despite the company's historical reliance on collaboration income.

Revenue

The total revenue of CRISPR Therapeutics increased by 1041.4% to $10.18 million in 2026 Q2, up from $892,000 in 2025 Q2. This substantial growth was primarily driven by collaboration revenue, which accounted for $10 million of the total. Additionally, grant revenue contributed $181,000, bringing the total revenue to the reported $10.18 million figure.

Earnings/Net Income

CRISPR Therapeutics narrowed losses to $0.94 per share in 2026 Q2 from a loss of $2.40 per share in 2025 Q2 (60.8% improvement). Meanwhile, the company successfully narrowed its net loss to $-91.15 million in 2026 Q2, reducing losses by 56.3% compared to the $-208.55 million net loss reported in 2025 Q2. The Company has sustained losses for 11 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Despite the persistent losses, the EPS beat indicates improved cost management or one-time gains relative to expectations.

Price Action

The stock price of CRISPR Therapeutics has climbed 3.18% during the latest trading day, has climbed 6.08% during the most recent full trading week, and has tumbled 10.88% month-to-date.

Post Earnings Price Action Review

Short answer: the strategy is not reliably profitable as a simple long-only “buy revenue miss, hold 30 days.” In biotech especially, revenue misses often get punished hard on the earnings day, but the 30-day follow-through is inconsistent because the market frequently reprices the rest of the story—guidance, pipeline, cash runway, dilution risk, and sentiment. So the edge, if it exists, is more likely in shorting revenue misses or trading earnings-gap setups, not in a broad long-only rule. Using the latest available U.S. equity proxy data, the broad market has been strong over the last year: SPY rose from $584.64 on January 2, 2026, to $757.67 on August 4, 2026, and QQQ rose from $244.79 to $545.46 over the same window.visual{"uuid":"7d902a9f-51c3-4f15-ae52-2b10cff5a563","type":"model"}

Recent market data illustrates that while revenue misses can trigger immediate sell-offs, as seen with Krystal Biotech and Sally Beauty, CRISPR’s revenue beat of $10.18 million against a $7.43 million estimate aligns with positive price action. The market appears to reward strong top-line performance even in volatile sectors, suggesting that conditional strategies focusing on beats and guidance are more reliable than broad miss-based rules.

CEO Commentary

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics, emphasized strong Q2 execution, citing CASGEVY’s 78% quarter-over-quarter revenue growth and FDA approval for children aged two and older. He highlighted the expansion of the in vivo pipeline with Phase 1 trials for CTX340 and CTX460, noting the company enters the second half of 2026 well-positioned with significant upcoming milestones. Kulkarni’s tone remains optimistic, underscoring momentum in hemoglobinopathies and diversified pipeline progress across cardiovascular, autoimmune, and regenerative medicine sectors.

Guidance

The company anticipates providing clinical updates for CTX310 (Phase 1b), CTX611 (Phase 2), and zugo-cel (autoimmune and immuno-oncology) during the second half of 2026. Management expects to announce an update on the CTX321 Lp(a) program in 2026 and has the option to nominate two additional siRNA targets for research, with updates also expected that year. Furthermore, CRISPR Therapeutics plans to advance CTX213 toward the clinic for Type 1 diabetes, continuing to leverage its proprietary platforms to expand addressable patient populations and drive pipeline development across multiple therapeutic areas.